Guidelines for community-acquired pneumonia in the ICU.
Community-acquired pneumonia remains a common and serious condition worldwide. Severe community-acquired pneumonia requiring ICU admission is a distinct entity with different pathogens, outcomes, and management. The mortality rate in severe community-acquired pneumonia can be more than 50%. Over the past decade, some international guidelines for the management of community-acquired pneumonia have been developed in an attempt to optimize patient care. These guidelines have developed prediction tools to direct clinicians in the management of community-acquired pneumonia, including when to admit a patient to the ICU and selecting appropriate investigations and antimicrobial therapy. The individual recommendations of these guidelines and the guidelines as a whole require further studies.
Wilkinson
Mark
M
Manchester Royal Infirmary, Manchester, UK.
Woodhead
Mark A
MA
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016993:Chlamydophila pneumoniae; D017714:Community-Acquired Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007362:Intensive Care Units; D016952:Legionella pneumophila; D018410:Pneumonia, Bacterial / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011550:Pseudomonas aeruginosa; D013296:Streptococcus pneumoniae; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents